Figure 1

Completed phase III trials of direct oral anticoagulants in the treatment of venous thromboembolism. (a) Primary efficacy outcome and (b) Major bleeding events [32],[33],[35]-[39]. *Non-inferiority test. ^†Superiority test. ^‡Principal safety outcome in EINSTEIN DVT and EINSTEIN PE was major or non-major clinically relevant bleeding. HR, hazard ratio; LMWH, low molecular weight heparin; NS, not significant; RR, relative risk; VKA, vitamin K antagonist; VTE, venous thromboembolism.